宏壮壮病:病理生理学考虑和治疗选择,包括口服索马托他类型的不断变化的作用
Charles P Daniel1, Maxwell J Wagner1, Grant E Borne1
1School of Medicine, Louisiana State University Health Sciences Center at Shreveport, 1501 Kings Highway, Shreveport, LA 71103, USA.
概括
Mycapssa® (八甲胺囊) 提供了有效的口服治疗巨,维持IGF-1和GH水平,根据患者的偏好. 对特定人群需要进一步研究.
科学领域:
- 内分泌学 在内分泌学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 巨症是一种罕见的激素疾病,其特点是生长激素 (GH) 和胰岛素类生长因子1 (IGF-1) 的过度产生.
- 壮症的传统治疗方法包括手术和注射性索马托斯坦类同类药物,这可能对患者造成负担.
研究的目的:
- 为了评估Mycapssa® (八类囊) 的疗效,安全性和患者偏好,这是FDA批准的第一个口服索马托斯塔丁受体连接体用于壮症治疗.
- 评估口服八胺在控制巨和IGF-1水平的作用,在巨患者.
主要方法:
- 该研究分析了多项临床试验的数据,包括开放标签 (CH-ACM-01) 和双盲安慰剂控制 (CHIASMA OPTIMAL) 研究,以及开放标签扩展 (CHIASMA OPTIMAL OLE).
- 评估了生物化学标志物 (IGF-1,GH),安全概况和患者报告的结果.
主要成果:
- Mycapssa®显示出IGF-1和GH水平的一致的生化正常化.
- 口服的八胺囊显示了与可注射索马托斯塔丁类似物相提并论的安全性.
- 患者表示,他们更喜欢继续用烯胺囊治疗,而不是注射.
结论:
- 八胺囊 (Mycapssa®) 提供了一种有效的口服替代品,用于壮病的管理,改善患者的坚持和满意度.
- 需要进一步的研究,以了解不同人群的长期疗效和安全性,包括女性和儿科患者.
相关概念视频
Glucagon-like Receptor Agonists
348
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
348
Hypoglycemia and Glucagon
287
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
287
Oral Hypoglycemic Agents: Biguanides and Glitazones
223
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
223
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
196
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
196
Oral Hypoglycemic Agents: Sulfonylureas
226
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
226
Major Hormones and Their Functions
473
Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
473


